Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.

ABSTRACT:

Background

Alpha-fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP), also known as protein induced by vitamin K absence-II (PIVKA-II [DCP]) are biomarkers for HCC with limited diagnostic value when used in isolation. The novel GAAD algorithm is an in vitro diagnostic combining PIVKA-II (DCP) and AFP measurements, age, and gender (biological sex) to generate a semi-quantitative result. We conducted prospective studies to develop, implement, and clinically validate the GAAD algorithm for differentiating HCC (early and all-stage) and benign chronic liver disease (CLD), across disease stages and etiologies.

Methods

Patients aged ≥18 years with HCC or CLD were prospectively enrolled internationally into algorithm development [n = 1084; 309 HCC cases (40.7% early-stage) and

SUBMITTER: Piratvisuth T 

PROVIDER: S-EPMC10635602 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature